Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer
ctDNA analysis has the potential to identify patients at elevated risk of recurrence, thus providing personalized treatment strategies for patients with resectable gastric and GEJ cancer. Further validation in larger cohorts and ctDNA-guided interventions are needed for future clinical use.
Authors
- Cecilie Riis Iden
- Tenna Vesterman Henriksen (ORCID: https://orcid.org/0000-0002-8541-1735)
- Kristian Egebjerg (ORCID: https://orcid.org/0000-0001-8781-8355)
- Sarah Østrup Jensen (ORCID: https://orcid.org/0000-0001-6044-3362)
- Lene Bæksgaard (ORCID: https://orcid.org/0000-0003-4662-5164)
- Nadia Øgaard (ORCID: https://orcid.org/0000-0003-0343-8369)
- Claus L. Andersen (ORCID: https://orcid.org/0000-0002-7406-2103)
- Mette Kjølhede Nedergaard
- Lise Barlebo Ahlborn (ORCID: https://orcid.org/0000-0001-8021-7442)
- Morten Mau‐Sørensen (ORCID: https://orcid.org/0000-0003-2235-1250)
- Michael Patrick Achiam (ORCID: https://orcid.org/0000-0002-3062-5138)
- Rajendra Singh Garbyal
- Salah Mohammad Mustafa
Institutions
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Gastric Cancer
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1007/s10120-024-01556-9
- Citations
- 16
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Kræftens Bekæmpelse
- Dansk Kræftforsknings Fond
- Novo Nordisk Fonden